PuSH - Publikationsserver des Helmholtz Zentrums München

Hensel, T.* ; Giorgi, C.* ; Schmidt, O.* ; Calzada-Wack, J. ; Neff, F. ; Buch, T.* ; Niggli, F.K.* ; Schäfer, B.W.* ; Burdach, S.* ; Richter, G.H.*

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Oncotarget 7, 1451-1463 (2016)
Verlagsversion DOI PMC
Free by publisher
Creative Commons Lizenzvertrag
Ewing sarcomas (ES) are highly malignant bone or soft tissue tumors. Genetically, ES are defined by balanced chromosomal EWS/ETS translocations, which give rise to chimeric proteins (EWS-ETS) that generate an oncogenic transcriptional program associated with altered epigenetic marks throughout the genome. By use of an inhibitor (JQ1) blocking BET bromodomain binding proteins (BRDs) we strikingly observed a strong down-regulation of the predominant EWS-ETS protein EWS-FLI1 in a dose dependent manner. This was further enhanced by co-treatment with an inhibitor of the PI3K pathway. Microarray analysis further revealed JQ1 treatment to block a typical ES associated expression program. The effect on this expression program was mimicked by RNA interference with BRD3 or BRD4 expression, indicating that the EWS-FLI1 mediated expression profile is at least in part mediated via such epigenetic readers. Consequently, contact dependent and independent proliferation of different ES lines was strongly inhibited. Mechanistically, treatment of ES resulted in a partial arrest of the cell cycle as well as induction of apoptosis. Tumor development was suppressed dose dependently in a xeno-transplant model in immune deficient mice, overall indicating that ES may be susceptible to treatment with epigenetic inhibitors blocking BET bromodomain activity and the associated pathognomonic EWS-ETS transcriptional program.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Bet Bromodomains ; Ewing Sarcoma ; Jq1 ; Pi3k Pathway ; Tumor Growth
ISSN (print) / ISBN 1949-2553
e-ISSN 1949-2553
Zeitschrift OncoTarget
Quellenangaben Band: 7, Heft: 2, Seiten: 1451-1463 Artikelnummer: , Supplement: ,
Verlag Impact Journals LLC
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pathology (PATH)